Branch Vein Occlusion Study

Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999

Keywords

ClinConnect Summary

Retinal branch vein occlusion (BVO) is the second most common retinal vascular disease after diabetic retinopathy. Many treatments for this disorder were attempted before 1977, but none were proven to be effective. The only treatment that seemed at all promising in preventing visual loss from BVO was laser photocoagulation.

Approximately 500 patients were enrolled in the study. One-half were randomly assigned to treatment with argon laser photocoagulation; the other one-half remained untreated as controls. For BVO with or without neovascularization, scatter treatment of 100 to 400 laser bu...

Gender

ALL

Eligibility criteria

• Patients with three types of diagnoses were accepted:
• • 1. major BVO without neovascularization;
• • 2. major BVO with neovascularization;
• • 3. BVO with macular edema and reduced vision. All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.